Author name: lehi@cogneo.com

ST. LOUIS, MO and SAN DIEGO, CA, April 7, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

ST. LOUIS, MO and SAN DIEGO, CA, March 24, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline

— WU-CART-007 granted FDA Orphan Drug Designation for the treatment of patients with relapsed or refractory (R/R) T-cell acute lymphoblastic

ST. LOUIS, MO and SAN DIEGO, CA, March 9, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline

WU-CART-007, an allogeneic off-the-shelf CAR-T cell therapy for T-Cell malignancies, has received IND clearance from the FDA   WU-CART-007 demonstrates

Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK)

ST. LOUIS, MO and SAN DIEGO, CA, November 10, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline

ST. LOUIS, MO and SAN DIEGO, CA, November 9, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline

ST. LOUIS, MO and SAN DIEGO, CA, November 4, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline